KURA vs. EXEL

In the year-to-date period, KURA achieves a -4.94% return, which is significantly lower than EXEL's 5.11% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current KURA Sharpe Ratio is -1.02, which is lower than the EXEL Sharpe Ratio of 2.20. The chart below compares the historical Sharpe Ratios of KURA and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither KURA nor EXEL has paid dividends to shareholders.

The maximum KURA drawdown since its inception was -87.15%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for KURA and EXEL. For additional features, visit the drawdowns tool.

Kura Oncology, Inc. (KURA) and Exelixis, Inc. (EXEL) have volatilities of 14.69% and 14.05%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Kura Oncology, Inc. and Exelixis, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.